[Characterization of patients with type 2 diabetes treated with vildagliptin].
| Autor: | Chambel P; Serviço de Endocrinologia, Diabetes e Metabolismo, Hospital Militar Principal, Lisboa, Portugal., Marcelino M, Domingues A, Vilar H, Lopes L, Paradinha M, Lopes MS, Carvalho R, Santos V, Jácome De Castro J |
|---|---|
| Jazyk: | portugalština |
| Zdroj: | Acta medica portuguesa [Acta Med Port] 2011 Jul-Aug; Vol. 24 (4), pp. 555-60. Date of Electronic Publication: 2011 Dec 12. |
| Abstrakt: | Introduction: Diabetes mellitus is a progressive disease and the rapid growth of this global prevalence has been a worldwide concern. About a third of Portuguese population has type 2 diabetes or pre-diabetes. 2 DM is associated with significant morbidity and mortality, although the treatment so far available it is a high percentage of patients who do not achieve the proposed objectives. Vildagliptin is an inhibitor of oral DPP-4, the most studied of this new class. Inhibiting the rapid degradation of incretins, the vildagliptin increases levels of GLP-1, getting this hormone available to modulate the function of a and ß cells. Aims: This study aims to characterize the first patients with DM2 treated with vildagliptin in the Department of Endocrinology, Diabetes and Metabolism at the Military Hospital. Methods: Retrospective study with the first 70 patients treated with vildagliptin, between October and December 2008. The information collected was demographic data, disease duration, associated diseases and their medication, metabolic control in the beginning of the disease (values HbA1c) and criteria for use of vildagliptin. Results: Among the patients included in the study, 55, 7% were male, with the average age of 63, 3 years. These patients had a average duration of diabetes of 11, 7 years. Hypertension was the most frequent associated pathology (85.7% of patients), although dyslipidemia and obesity have a high percentage, 80% and 51% respectively. All patients were overweight (BMI =25 Kg/m(2)). More than half of the patients (55,7%) were on monotherapy until the introduction of vildagliptin, having been associated with other oral antidiabetic agents in all patients. Conclusions: Most of patients showed risk factors, for witch they were medicated. Vildagliptin has been added mostly in patients medicated with metformin. It is suggested that the therapeutic approach in type 2 diabetes is more and more early, effective and secure. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|